Solid Tumors, Adult Clinical Trial
Official title:
A Single-arm Phase I Clinical Study of TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors
This is a multicenter, single-arm phase I clinical trial.The study process was divided into: screening period, sampling and production period, clear lung pretreatment period, treatment and observation period, and follow-up period.
Status | Recruiting |
Enrollment | 20 |
Est. completion date | April 21, 2024 |
Est. primary completion date | April 21, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - 1. The Patients (or legally authorized representative) Patients (or legally authorized representative) must have the ability to understand the requirements of the study, have provided written informed consent as evidenced by signature on an informed consent form (ICF) approved by an Institutional Review Board/Independent Ethics Committee (IRB/IEC), must have the ability to understand the requirements of the study; - 2.Must have a confirmed diagnosis of malignancy of their receptive histologies or cytologies: unresectable recurrent or metastatic solid tumor; - 3.At least one resectable lesion (preferably superficial metastatic lymph nodes) that has not been treated with radiation and has not received other local therapies. The separated tissues mass weighing =1.0g (either of single lesion origin or multiple lesions combined) for the preparation of autologous tumor-infiltrating lymphocytes. Minimally invasive treatment where possible; - 4.Any anti-tumor therapy should be stopped at least 28 days before NMA lymphodepletion pretreatment; Exclusion Criteria: - 1. Patients who have symptomatic and/or untreated CNS metastases (Except stable brain metastases, no medication required within 3 months, no hormone dependence); - 2.The patient who has any active autoimmune disease, history of autoimmune disease, need for systemic steroid hormones or a condition requiring immunosuppressive drug therapy (>10 mg/day of prednisone or equivalent hormone); - 3. Arterial/venous thrombotic events within 5 months prior to enrollment, such as: cerebrovascular accident, deep vein thrombosis and pulmonary embolism occurring; - 4.Active infections requiring treatment with systemic anti-infectives (except for topical antibiotics); or those with unexplained fever > 38.5? occurring during the screening period, except for tumor fever; - 5. Patients who have refractory or intractable epilepsy, poorly controlled hydrothorax, hydrops abdominis, active gastrointestinal bleeding or IL-2 contraindications; - 6. Participate in other clinical trials within 28 days prior to the first dose of this study, or planning to participate in this study and other clinical trials at the same - 7. Patients who have received allogeneic bone marrow transplantation or an organ allograft; - 8.Patients who have a history of hypersensitivity to any component or excipient of study drugs: autologous tumor infiltrating lymphocytes, cyclophosphamide, fludarabine, IL-2, dimethyl sulfoxide (DMSO), human serum albumin (HSA), dextran-40 and antibiotics (beta lactam antibiotics, gentamicin); |
Country | Name | City | State |
---|---|---|---|
China | The Affiliated Hospital Of Xuzhou Medical University | Xuzhou | Jiangsu |
Lead Sponsor | Collaborator |
---|---|
Grit Biotechnology |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety Profile Measured by Grade =3 TRAEs | Safety Profile Measured by Grade =3 TRAEs by CTCAE 5.0 | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06404528 -
Low-dose Chemotherapy Under Hypoglycaemia for the Treatment of Relapsed Refractory Advanced Solid Tumours
|
N/A | |
Terminated |
NCT04467853 -
A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT05698888 -
Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04587479 -
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT05472220 -
Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma
|
Phase 1 | |
Recruiting |
NCT05354323 -
NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05430373 -
GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04739293 -
Study of ON 123300 in Patients With Advanced Cancer
|
Phase 1 | |
Not yet recruiting |
NCT05747339 -
A Clinical Study on the Efficacy and Mechanism of Tumor Treatment Vaccine (TTV) for Recurrent and Refractory Advanced Solid Tumors
|
N/A | |
Recruiting |
NCT05887492 -
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05228015 -
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT05018273 -
Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04621435 -
Imaging of Solid Tumors Using FAP-2286
|
Phase 1 | |
Recruiting |
NCT05861895 -
A Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05768139 -
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 |